Drugs in Dev. Infections and Infectious Diseases
Phase I
Spain 
Lead Product(s) : GIGA-2050
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GIGA-2050 is comprised of more than 12,000 antibodies demonstrating strong neutralizing activity against natural SARS CoV-2 variants in laboratory studies, including the delta variant and other variants that have emerged globally since the beginning of t...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 11, 2021
Lead Product(s) : GIGA-2050
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Apices Soluciones
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PharmaMar’s cancer drug Aplidin (plitidepsin) has demonstrated ‘potent preclinical efficacy’ against SARS-CoV-2, the virus which causes COVID-19. Aplidin inhibits the eEF1A protein, which is associated with the SARS-CoV-2 virus.
Product Name : Aplidin
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 26, 2021
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Apices Soluciones
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
PharmaMar Plans Phase III Trial of Cancer Drug for COVID-19, Shares Jump
Details : There was a substantial reduction in viral load and the C-reactive protein (CRP) in patients, and that 80.7% of patients had been discharged before the 15th day of hospitalisation, and 38.2% before the eighth day.
Product Name : Aplidin
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 16, 2020
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Apices Soluciones
Deal Size : Inapplicable
Deal Type : Inapplicable
Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19
Details : Plitidepsin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 11, 2020
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Apices Soluciones
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DNA.HTI
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DNA.HTI is a Oligonucleotide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of HIV Infections.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
July 02, 2017
Lead Product(s) : DNA.HTI
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Ivermectin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Helminthiasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 02, 2017
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rabies Immune Globulin (Human)
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RIG-C (Rabies Immune Globulin (Human)) is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Rabies.
Product Name : RIG-C
Product Type : Vaccine
Upfront Cash : Inapplicable
May 15, 2014
Lead Product(s) : Rabies Immune Globulin (Human)
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated,Live-Attenuated Mycobacterium Tuberculosis Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Universidad de Zaragoza | Centre Hospitalier Universitaire Vaudois | TuBerculosis Vaccine Initiative
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MTBVAC (Live-Attenuated Mycobacterium Tuberculosis Vaccine) is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Tuberculosis.
Product Name : MTBVAC
Product Type : Vaccine
Upfront Cash : Inapplicable
December 17, 2013
Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated,Live-Attenuated Mycobacterium Tuberculosis Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Universidad de Zaragoza | Centre Hospitalier Universitaire Vaudois | TuBerculosis Vaccine Initiative
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
